Contents

2 Editorial
4 News
6 Interviews:
   >>venture>>
   Fights COVID-19
20 The Winners 2020
34 >>venture>> 2020 in Numbers
40 Media
42 Success Story:
   Planted
52 Advisory Board
54 Mentors and Jurors
56 The >>venture>> foundation
Dear Reader,
It has undoubtedly been a difficult year. Yet besides the challenges, the pandemic has also shown how humanity is capable of dealing with seemingly intractable problems. And in the midst of it all: two startups. The vaccines produced by Moderna (founded in 2010) and BioNTech (2008) were the first to be approved in the Western world, and they are playing a key role in combating the virus.

>>venture>> companies have also been actively involved in tackling the crisis: Molecular Partners is working on a COVID-19 drug that is due for rollout at the end of the year; HeiQ has supplied over a billion products with antiviral protection; SOPHiA GENETICS is helping with early detection of new variants of the virus … Interviews with these companies start on page 6.

The only way out of the crisis is through innovation. In a bid to address another challenge facing humanity, climate change, Planted is producing plant-based meat. Read our profile on page 42.

Startups can create societal value through their products. And that’s not the whole story. A study conducted by the University of Lausanne and the news portal Startupticker.ch concludes that new companies in Switzerland employ around 50,000 people—comparable to the workforce of the country’s entire pharmaceutical industry. Moreover, job growth in startups stands at 3.7 percent, three times higher than the average across the Swiss labor market.
We estimate that >>venture>> companies have created way above 10,000 jobs since our foundation in 1997. And I'm particularly thrilled to note that the COVID-19 year has seen a real explosion in participant numbers—with 31 percent more teams taking part in 2020 as compared with the previous year.

Our current assumption is that we will be able to hold our award ceremony at ETH Zurich on September 13, 2021. If all goes to plan, I will be delighted at long last to once again be in a position to welcome you in person.

Thomas Knecht,
founder of >>venture>>
HEIQ'S INNOVATIVE PATH TO THE STOCK EXCHANGE

On December 7, 2020, the winner of >>venture>> 2006 premiered on the London Stock Exchange with a stock package worth GBP 60 million. The Schlieren-based company specializing in textile innovation went public by means of a reverse takeover, meaning it took over an already listed SPAC, or special purpose acquisition company. According to HeiQ, this path saved the company a third of the time needed for a conventional IPO as well as 20 to 50 percent of the cost. Among the many technologies at its disposal, HeiQ, a spin-off of ETH Zurich, developed an antiviral textile treatment that offers protection from SARS-CoV-2 transmission and can be used for face masks. HeiQ launched at a share price of GBP 1.12—the company is now trading at 1.39 (9 July 2021). Interview on p. 16.
Bloom Biorenewables, a >>venture>> winner from 2019, brought a prominent investor on board in 2020: Bill Gates participated in the seed round, resulting in EUR 3.9 million, with his investment company Breakthrough Energy Ventures-Europe (BEV-E). Bloom is a spin-off of EPFL and develops innovative biomass fractionation technologies.

>>VENTURE>> WELCOMES NEW PROMINENT MEMBERS
We are delighted to welcome Doris Leuthard onto the foundation board starting in summer 2021. For many years, the former Swiss Federal Councillor has lent her support to our competition: for example, giving the keynote as president of the Swiss Confederation at the >>venture>> award ceremony in 2010. >>venture>> would also like to extend a warm welcome to the new members of the advisory board: Philipp Rickenbacher from Julius Bär, Jürgen Eckhardt from Bayer Leaps, Carlo Centonze from HeiQ, and Walter Vogel from Skyguide who joined this year. An equally warm welcome goes to Patrick Amstutz from Molecular Partners and Arnd Kaldowski from Sonova who are back on the advisory board after taking some time away.

>>VENTURE>> GOES ZOOM
The last >>venture>> award ceremony took place virtually on June 22, 2020. The event was hosted online and was a major success: more than 10’000 viewers watched the one-hour event, among them the majority of the Advisory Board.
VENTURE FIGHTS COVID-19

SOPHiA GENETICS >>>venture winner 2012  page 7
The company for data-driven medicine sequences and monitors the spread of SARS-CoV-2.

Molecular Partners >>>venture winner 2004  page 11
The biotech company is developing a COVID-19 drug.

HeiQ >>>venture winner 2006  page 15
The company for textile innovation has reactivated a virus blocker from the Ebola era and successfully treated over a billion products with it.
How have you been since January 2020?
How has your company fared?

It’s been a strange year for everyone, but we were lucky enough to get out of it relatively unscathed, as a company. Our core area of expertise made it quite easy to adapt to remote working and we managed not only to survive but to achieve important results and reach some new milestones.

SOPHiA GENETICS sequences the COVID-19 virus to track mutations. When did you decide to focus on SARS-CoV-2 and why?

In March last year, we responded by reallocating resources to the fight against infectious diseases, and specifically COVID-19. We used our expertise and technological capabilities to develop a solution based on next-generation sequencing to follow the evolution of the virus over time at the genomic level. The idea behind this was mainly to support the global epidemiology efforts and to work with our pharmaceutical industry partners to accelerate the development of vaccine candidates and antiviral therapeutic approaches.

"What doesn’t kill you makes you stronger!"

As a leader in data-driven medicine, SOPHiA GENETICS applied its expertise to the sequencing of the SARS-CoV-2 genome to detect mutations at an early stage and monitor the virus’s evolution on a global scale. Cofounder and CEO Jurgi Camblong comments on an extraordinary year in which his company has fought the virus and secured a US$110 million round of funding along the way.
In August 2020, we went further with the addition of data analytics capabilities in medical imaging (using CT scans and lung segmentation to quantify disease), allowing us a better understanding of how disease progresses.

**What successes have there been?**
Like any virus, SARS-CoV-2 evolves and adapts constantly. We knew it would be important to sequence and monitor its genome to identify new strains and support informed health policies. Our cloud-based SOPHiA DDM Platform has received a lot of attention over the past few months for its COVID-19 surveillance. With over 6,000 samples per month now in eight countries, we are able to see how the virus evolves in genomic terms as well as geographically and over time. We have seen an increase in the frequency of such mutations, indicating that an early spread of these mutations is already happening. SOPHiA DDM is now a unique asset to support the real-time global surveillance of COVID-19.

**In October 2020, you successfully secured an oversubscribed US$110 million Series F funding round. Was that easier or harder than it would have been during “normal” times?**
This funding round was certainly different because of the virtual nature of the interactions. I guess our advantage was that we were already well known in the investment community, where we have a solid and consistent track record. In addition, given that this was not our first time raising capital, we were pretty well equipped and organized to manage the operational aspect of the transactions.

**Generally, from your point of view, what is the impact of the pandemic on the Swiss startup universe?**
When it first hit, the pandemic took its toll on most companies, and for fledgling startups it was hard. I hope and believe that these setbacks will not have any impact over the long term. Business and investment opportunities were probably a bit scarcer than usual, but if a company can make it through a pandemic, it can rest assured that it can make it through anything. What doesn’t kill you makes you stronger!

**Jurgi Camblong (43)** is cofounder and CEO of SOPHIA GENETICS, a leader in data-driven medicine and listed among the fifty smartest companies by the MIT Technology Review. Jurgi Camblong is a molecular biologist with a PhD in life sciences from the University of Geneva and an EMBA in technology management from EPFL/HEC Lausanne. He has been a member of the Swiss Federal Government’s advisory council on digital transformation and was recognized by EY as Emergent Entrepreneur of the Year 2017. >>venture>> winner 2012
Patrick Amstutz (46) holds a PhD in molecular biology (University of Zurich) and is the cofounder, CEO, and member of the board of directors of Molecular Partners, a listed biotech firm advancing a growing pipeline of DARPin® therapeutics for the treatment of severe or life-threatening diseases with an initial focus on ophthalmology and oncology. In March 2020, the Schlieren-based company started a program to develop a drug against COVID-19.

>>venture>> winner 2004
How have things been for you since January 2020?
Things have definitely been pretty lively for us since the start of last year. You might say that we’ve had three waves of our very own—both within the organization and in terms of the share price. We started last year on a high, fully expecting to be getting our first product, abicipar, an eye drug, onto the market in 2021 at the latest and thus giving rise to regular sales. This is a key milestone for every biotech company, and it generated positive expectations both on the financial market and for us as a company. You could call this the first positive “wave.” We also successfully launched our COVID-19 program, which brought us even more into the spotlight. But the first positive wave ended abruptly, firstly with the sharp market correction at the end of March 2020 and then when the FDA unexpectedly refused to approve abicipar. Our share price plummeted, and confidence crumbled all round.

But good news was just around the corner?
Yes. Our second—positive—wave began in July when we secured some illustrious new US investors, and the Swiss Federal Office of Public Health (BAG) decided to support Molecular Partners is developing a COVID-19 drug that might soon be market-ready, despite its being a company with “almost no experience in virology,” as cofounder, CEO, and member of the advisory board Patrick Amstutz put it.
Molecular Partners decided back in March 2020 to push ahead with developing a drug against COVID-19. How did this decision come about?

In March 2020, my team and I were at a biotech conference in Boston when COVID-19 suddenly became a very palpable reality, both in the industry and in the wider world. It coincided precisely with a superspreader event hitting the headlines—in Boston of all places. We were seeing images from Italy of dead bodies being taken away in trucks. We were all deeply shaken and started thinking about whether we could perhaps use the versatility of our DARPin® platform in the global fight against COVID-19. And?

It was our current COVID project manager, Marcel Walser, team manager on the research side, who really pushed the idea consistently and relentlessly. It didn’t take long before we all wanted to demonstrate that DARPin® drugs could be a key component on the road to victory over the virus. Bill Lee, a former member of the board of directors, also played a key role as head of research at Gilead, a leading virology company. Bill was also encouraging us to start a COVID-19 program. After that, Marcel sent out an internal mail to all company employees asking if they would back his new project. The response he received was overwhelming and very positive.

What’s the best-case scenario for your COVID-19 program?
The best case is, of course, that we all “beat” COVID-19 together. And the “best of all possible cases” would be if Molecular Partners and Novartis had made a major contribution to the fight. If everything continues to develop according to plan, we have good a chance of getting emergency approval for ensovibep. If that happens, the drug could be available by the end of fall—in an area where, just over a year ago, we had nothing.

**Why does the world need ensovibep now that we have a vaccine?**

To date, ensovibep maintains full activity against all known virus variants. This is not the case for several monoclonal antibodies. And it’s also not clear yet how well the vaccines protect people against such expected mutations of the virus. So ensovibep can also be characterized as an insurance policy against future mutations. MP0423—our second COVID-19 drug—represents another insurance policy against potential new mutations that are unknown today, and against which ensovibep may be less effective. MP0423 works in a slightly different way. It attacks the spike protein of the virus in two more places, effectively blocking another two of its escape routes. It could also make a lot of sense to mix ensovibep and MP0423 into a cocktail that combines the advantages of both drugs. This is an approach, for example, used by antibody-based companies such as Regeneron. But first we have to demonstrate the safety of MP0423 in a Phase 1 trial.

**If MP is able to get the drug ready for market, what will that mean for the future of the company?**

It would be an overwhelming success for the company and for our entire DARPin® technology platform: it would translate into a high level of international credibility and visibility and boost the value of our entire platform. After all, it would mean that we had developed an effective COVID drug in just over a year. And it would be nice to also see market success for ensovibep. That would benefit both Molecular Partners and our shareholders. Because over and above the sales of ensovibep, or rather its licensing revenues, we would also get CHF 150 million as soon as Novartis decides to execute its option to inlicense ensovibep. This payment is not linked to whether another drug outperforms ensovibep on the market.

**And if it doesn’t happen?**

If something goes fundamentally wrong during development and ensovibep is discontinued, then we can still rely on our oncology pipeline, which we have consistently maintained, as well as our solid balance sheet and strong cash position. Even without the revenues from our COVID-19 program, we are very comfortably financed for two more years, and we have other valuable programs.

**Have you had to put the development of other drugs on hold?**

The focus last year was, of course, most definitely on developing our COVID-19 drugs as rapidly as possible—because results
here are desperately needed, for all of us. But the teams in oncology have continued according to plan. Only recently, in April 2021, at the renowned AACR conference in the US, we presented four posters on our innovative new programs in this field of immuno-oncology. For the Phase Ia immune-oncology trial, which we are working on with our partner Amgen, it was also possible to recruit patients pretty much to plan. The few delays they did experience stemmed from the fact that hospitals and their resources were so heavily burdened and, in some cases, overloaded by the pandemic.

**What’s the difference between developing a COVID-19 drug and “normal” development?**

If I said “faster progress,” that would actually be a bit of an understatement. Within a year, we had moved from the initial idea to the clinic and have already stepped into the first pivotal trial. A timeline like this was previously unthinkable in our industry. It’s a source of great pride for us, particularly as a company that had almost no experience in virology.

**And how has the industry developed in general?**

It has rediscovered the concept of “co-opetition.” In certain areas, pure competition has given way to cooperation. Examples here are new consortia such as ACTIV in the US and Agile in the UK with their standardized protocols and pool of recruited patients. It’s a quantum leap for our sector.

Negotiations and cooperation contracts have also been finalized significantly faster than in the past—so, too, in our case with Novartis, where we wrapped things up in a matter of weeks. The same can be said of collaborations with external partners like universities or other research institutions and labs—in our case, Labor Spiez and universities in Utrecht, Berlin, and Lausanne. The sector worked extremely efficiently under a great deal of pressure and in many cases 24/7. Here, processes that would normally be sequential have been run in parallel. This makes things go a lot faster, but it also significantly increases the financial risk. The regulatory authorities also felt the pressure and maxed out their time frames without compromising patient safety. So we were under a lot more scrutiny, not only from our partners and the authorities but also from other stakeholders such as the media and investors, and we did our best to be transparent and make ourselves available to them at all times.
“A timeline like this was previously unthinkable.”

Patrick Amstutz, cofounder and CEO, Molecular Partners
Carlo Centonze (47) is cofounder and CEO of HeiQ, a leader in textile innovation, headquartered in Schlieren near Zurich. HeiQ is a spin-off of ETH Zurich, where Centonze earned his engineering degree. The name HeiQ is a play on the words “high-quality” and “intelligent materials.”

venture winner 2006
What has been your experience of the period since January 2020?
It has been a transformative and momentous time for HeiQ, characterized by fast growth. January 2020 was the start of an extremely eventful year at HeiQ. I looked on in disbelief at what was happening in Wuhan and realized that the world was about to face a pandemic. This prompted me to pull out a tried and tested antiviral technology, HeiQ Viroblock, which had been launched during the Ebola epidemic in 2013 and had proved effective on surgical masks and medical gowns and gloves—this is right in line with our company motto and our dedication to improving the lives of billions of people through pioneering textiles and materials innovation. We were ready to deploy this technology right after the Swiss government announced a state of emergency in March 2020. And, as the saying goes, the rest is history.

Sure, but please do tell us a bit more about what happened next.
HeiQ Viroblock NPJ03 went into large-scale production within six weeks, and we started supplying the first antiviral masks to Swiss hospitals. The global demand then simply exploded. Thanks to an agile team, we mobilized a global task force and worked relentlessly to serve this urgent need. We were deploying resources to prepare our IPO for the London Stock Exchange Main Market, while at the same time making sure
not to neglect our other textile technologies and customers. In short, you can say it’s been a pretty hectic year but, fortunately for us, positively so.

**How are things looking now?**
At the end of 2020, before any jab with the COVID-19 vaccine had been administered, we had already treated over one billion face masks, gloves, and countless other textile and non-textile materials with HeiQ Viroblock… But the end of the tunnel is still not in sight, which is why we need to continue taking precautions and protecting ourselves.

**How does the HeiQ Viroblock work, and what can it be used for?**
HeiQ Viroblock is a fast-acting antiviral technology consisting of a combination of silver molecules, which destroy viruses, and vesicles, which break down the viral membrane. It is also effective against other pathogens (avian flu, H1N1) and bacteria. With people being more hygiene conscious and aware of the threat of viruses and bacteria in their surroundings, HeiQ Viroblock is proving to be extremely versatile. Although it was originally conceived as a technology for textiles, it has recently been applied to paint emulsions for home paints and to coatings for printing processes such as commercial print, food, beverage, and pharma packaging.

**HeiQ won the Swiss Technology Award 2020, and the IPO was a great success. How much has the company benefited from COVID-19?**

No one could benefit from COVID-19. Everyone is suffering, either from the disease itself or as a result of the pandemic measures in place or the slowdown in the economy and insecurity about the future. I would say HeiQ is proud to have been able to help mitigate the situation. We quickly reprioritized resources to focus on producing and organizing the supply chain for pandemic-relevant products, with the goal of trying to contribute in the best way we could. We thought it would take a while for a vaccine or cure to be invented. So while the pharmaceutical industry was doing their job, we did ours and tried our best to ease the situation as much as possible by doing what we are good at. All HeiQ employees rolled up their sleeves to help, and that’s how we achieved what we achieved in 2020. This strong team has impressed me, and I am sure our strength will bring us many more successful years to come.

**What is the most important thing you’ve learnt from the COVID-19 crisis?**
It has highlighted that innovation is in our DNA and that we must stay agile and continue to create, innovate, and anticipate, staying one step ahead of the curve at times when technologies and social needs and demands are evolving at a rapid pace. It has underlined the high value of all our partners around the world, be it research partners who keep us on our toes or brands and other collaborators demanding technological innovations that meet and exceed consumer wishes whilst being ecologically sound.
“All our employees rolled up their sleeves to help.”

Carlo Centonze, cofounder and CEO HeiQ
1. UrbanDataLab is a B2B web service offering advanced location analytics and customized business intelligence to enable smarter location-based business decisions on a global scale. Real-estate agents are UrbanDataLab’s main customer segment. The company provides them with a strategic decision-making tool delivering three services: site scouting, location evaluation, and portfolio management. UrbanDataLab is an ETH Zurich spin-off founded by two architects and a statistician. One of their first clients is Lägern Wohnen, a housing cooperative with 917 apartments.

Location: Zurich  
Affiliation: ETH Zurich  
Mail: mail@urbandatalab.net
2. **Stableton**’s alternative investment Fintech platform is striving to become the world’s leading market network for qualified and institutional investors seeking exposure to liquid alternatives, private equity, venture capital, private debt, and real assets. Their platform investors benefit from easy access, unique opportunities, performance, and measurable impact across absolute return strategies and alternative investment content from world-class investment providers. Providers of alternative investments benefit from a scalable, fully-digital, and data-driven infrastructure that enables effective and efficient lead generation and distribution.

*Location* Zug  
*Affiliation* Hohenheim University (D), Munich Business School (D), International School of Management (D), Zeppelin University (D)  
*Mail* info@stableton.com

3. **Z22 Technologies** is a financial research and quantitative asset management company and a spin-off from ETH Zurich and the University of St. Gallen (HSG). Z22 Technologies specializes in applying financial machine learning to asset management. The flagship product Z22 Smart Mirror combines an AI-optimized long US equity portfolio with a low-exposure momentum strategy to long volatility spikes as a hedge against market downturns. In October (2019) Z22 made the strategy available to external investors and launched an AMC (Actively Managed Certificate) with an initial volume of USD 250k together with UBS. In the meantime, Z22 is managing well above USD 100 m and was able to generate a net performance of more than +46.3% for their clients in 2020 during one of the biggest stock market crashes since 2008.

*Location* Cham  
*Affiliation* University St. Gallen (HSG)  
*Mail* hello@z22.ch

**FINALISTS**

| Aequitec | CurioInvest | Delega | Fidectus |
| Mt Pelerin | SIBEX | VALK |
1. **Urodea**’s patent-pending technology is the world’s first non-invasive solution for urinary retention. The hand-held device produced by the University of Bern spin-off helps generate a urine flow for emptying the bladder while avoiding contact with urine. The device is battery-powered and relatively small. It can be carried in a pocket and utilized when in the bathroom.

Having a bladder that always feels partially full, urinary tract infections, frequent visits to the bathroom at night, and a weak or intermittent urine stream are common experiences for sufferers of urinary retention. These symptoms significantly impact quality of life, causing pain, sleep disruption, embarrassment, and reduced self-esteem.

**Location** Bern  **Affiliation** University of Bern  **Mail** francesco.clavica@urodea.com
2. **Neurosoft Bioelectronics** is developing next-generation soft, implantable electrodes to interface with the nervous system. Therapeutic outcomes are limited by the mechanical properties of the clinical neural implants currently in use. Their stiff, rigid designs are ill suited to the soft, sinuous tissues with which they interface, constraining the physiological motion dynamics of the nervous system.

The EPFL spin-off addresses this issue by engineering elasticity in thin film materials to manufacture implantable electrodes that are much softer and more flexible and seamlessly interface with the nervous system.  

*Location* Geneva  
*Affiliation* EPFL  
*Mail* contact@neurosoft-bio.com

3. **NextKidney** is promising to deliver the “first truly portable home hemodialysis device.” Hemodialysis is a procedure in which a dialysis machine and a special filter known as an artificial kidney, or dialyzer, are used to clean the blood. Today, hemodialysis is performed in doctors’ offices or hospitals. Kidney patients typically need to receive this treatment three times a week, with each session lasting about four hours.

NeoKidney is the first hemodialysis device that is truly portable (weighing less than 10 kg), physiological, and cost effective. It will improve quality of life and provide substantial savings to both patients and healthcare systems.

*Location* Lausanne  
*Affiliation* n/a  
*Mail* info@nextkidney.com

**FINALISTS**

| Emovo | HexagonFab | Limula Biotech |
| MotionTech | Nemis Technologies | Rea |
| Terapet |
1. **kaiosID** supports brands in achieving two goals: eliminating counterfeiting with its elegant and secure traceability solution and increasing consumer engagement and trust. How does it work? Users scan products with the kaiosID-app to authenticate their purchase. At the same time, the app generates and tracks customer responses to advertising campaigns in real time and thus increases loyalty and trust.

**Location** Lausanne/Renens  
**Affiliation** n/a  
**Mail** info@kaiosid.com

2. **BLP Digital** is using AI to automate document-based Enterprise Resource Planning (ERP) and accounting workflows, such as invoice control, delivery note administration, and registering orders. The company’s value proposition promises a processing time that’s twenty times faster, with a 70 percent reduction in administrative costs—
and with only two days required for implementation. BLP Digital AG began developing its technology in 2018 at ETH Zurich. The company was founded in 2019 by a team of ten thoroughbred entrepreneurs and pioneers of machine learning, with the bold vision of liberating human beings from repetitive, mind-numbing tasks and allowing them to focus on more meaningful creative work. Ultimately, BLP is driven by the prospect of making significant socioeconomic change for the better.

Location Zurich  Affiliation ETH Zurich  Mail info@blp-digital.com

3. **SO REAL Digital Twins** uses its scanning and conversion technology (patent pending) to automate the production of digital twins of 3D objects. The Bern-based startup mass-produces assets for use in games, films, and XR experiences. The resulting objects are of cinematic quality and game- or XR-ready.

Further applications include AR retail (customers can experience products in artificial reality) and industry (individual components or complete assemblies). Ultimately, SO REAL aims to make the world a smaller place by enabling global access to immersive experiences and thus accelerating the journey to global understanding.

Location Bern  Affiliation n/a  Mail contact@soreal.ch

**FINALISTS**

| advaisor | Agrinorm | Exnaton | Typewise | Urbio | V-Labs | Zoundream |
1. Oxyle provides a robust and efficient catalyst for the complete elimination of organic contaminants from wastewater. Oxyle’s patented technology employs clean energy and sustainable materials and is easily scalable. It serves a range of customer segments, such as pharma and biotech, the chemical industry, food and beverages, R&D laboratories, hospitals, and many more.

Its nanotech solution efficiently and nonselectively destroys organic pollutants from wastewater: pesticides, insecticides, color pigments, and industrial chemicals. The ETH Zurich startup supports customers in their sustainability efforts and is motivated by the desire to make a positive socioeconomic impact.

Location Zurich  
Affiliation ETH Zurich  
Mail mail@oxyle.ch
2. **Swiss Ocean Tech**’s solution AnchorGuardian provides safe anchoring at any time for crew and passengers by minimizing the risk of anchor dragging, providing immediate, fail-safe anchor-dragging alarms, and predicting the anchor hold. This keeps crew and passengers safe, prevents damage to vessels, and minimizes the environmental impact. With its patented, disruptive technology, AnchorGuardian provides safety for leisure boats, fishing vessels, and merchant ships alike. The startup from Bremgarten (AG) was founded by Thomas Frizlen and his five cofounders. Thomas is a keen sailor and seasoned industrial economics expert with twenty years of experience at ABB, Alstom, and other companies.

*Location* Bremgarten  
*Affiliation* n/a  
*Mail* thomas.frizlen@swissoceantech.com

3. **RAAAM** has developed a unique on-chip memory technology, which enables up to 50 percent higher on-chip memory density, requiring no additional process steps or cost. The patented technology has been proven in silicon with the test chips of leading semiconductor foundries. The current growth drivers of the ICT industry, such as AI and machine learning, 5G, Internet-of-Things, and automation require ever-increasing levels of on-chip memory to minimize bandwidth-limiting and power-hungry, off-chip memory accesses. But on-chip embedded memories rely on the chip having a significant surface and consume a considerable amount of power. RAAAM offers the highest-density embedded memory in standard CMOS processes.

*Location* Ecublens  
*Affiliation* EPFL  
*Mail* info@raaam-tech.com

**FINALISTS**

| Abstract | Capskin | Gilytics | INERGIO | matriq | Miraex | Mithras Technology |
1. **Nuniq** is the only beauty brand that offers natural, personalized routines with a dramatic cut in plastics, for consumers that worry about the planet and want great results and greater hair. The two Spanish founders live in Terre Sainte, near Nyon (VD), and have backgrounds in marketing and design innovation. According to their vision: “We envision a world where there is beauty with no guilt. Our goal is to be the company that led the plastic-free movement in beauty by disrupting the industry through transparent innovation offering products that are made for you.”

*Location* Commugny  
*Affiliation* n/a  
*Mail* hello@nuniq.io

2. **Traverz** promises to deliver the “ultimate online product search experience.” Its AI-driven search engine for marketplaces and e-commerce replaces frustrating filters and search bars with an intuitive user
feedback system and a preference-ranking approach, resulting in happier users and faster conversions. The company was born in 2018 with the mission to “humanize search.” Its concept was a response to frustration with the traditional filter system, which has remained largely unchanged for more than two decades. In the long term, Traverz wants to apply its paradigm to other areas that apply user-based search and discovery, from Internet research to knowledge-based applications and internal enterprise searches. Traverz was founded by two AI specialists and proven entrepreneurs.

Location Zurich  Affiliation n/a  Mail contact@traverz.com

3. mia&noa operates the world’s first zero-waste, zero-contact coffee bar controlled by the customer’s smartphone. How does it work? Users select and personalize their coffee with the help of an app and receive a QR Code that they then scan at a mia&noa coffee bar, where the brew is poured into their own cup. mia&noa addresses both environmental concerns and the increased demand for hygiene in a completely touch-free solution. A family business from Geneva, mia&noa is named after Switzerland’s most popular first names. The company’s pilot coffee bar opened last summer at a train station, and more bars are being installed in educational institutions, corporate offices, and other attractive locations.

Location Geneva  Affiliation n/a  Mail info@miaetnoa.ch

FINALISTS

| Amplify | Caulys | Flunky | PriceHunterApp | Recyclage-express.ch | TeachNOW | Whering |
2020 >>venture>> Audience Award

The Audience Award is presented together with >>venture>> media partner RTS (Swiss Radio and Television). The TV audience and general public were invited to vote for their favorite team, with the winner awarded CHF 10,000.

Rea has developed a smart panty liner that analyzes vaginal secretions and alerts a doctor via a mobile app if the expectant mother needs to go to the hospital. Pregnant women at risk of preterm birth can spend up to three months in the hospital, although only 30 percent of them actually deliver preterm. This solution allows pregnant women to be monitored in the comfort of their own homes, potentially sparing them months of unnecessary hospitalization and over-medication. Rea is an EPFL spin-off; its two founders have backgrounds in biotechnology and microelectronic wearables.

Location Lausanne  Affiliation EPFL  Mail erick@reatest.ch

OTHER FINALISTS

| Caulys | CurioInvest | Oxyle | Zoundream |
>>venture>> 2020 in numbers

>>venture>> 2020 supported...

327 accepted submissions

+30% increase from last year

5166 business case registrations
... and delivered

85 mentorship pairings
173 jurors
13 events with ...
397 attendees
241 intellectual property voucher requests
Submissions per category Teams are active in five industry verticals, with Health & Nutrition attracting most participants.

Total number of accepted submissions: 327
University affiliation ETH Zurich and EPFL account for 43 percent of >>venture>> participants.

Number of individuals $327 = 100\%$

Gender Highest female participation rate in the history of >>venture>>.

in percent

77\%

23\%
Geography is a truly Swiss competition with participating teams from all parts of the country.

Total number of accepted submissions: 327
MEDIA REACH

>>venture>> 2020 enjoyed broad coverage across the Swiss media. The competition winners and alumni were featured in the national and local media on television, radio, in print, and online. The combined media reach was over 2.05 million accumulated visits.
WINNERS OF THE SWISS STARTUP AWARDS TAKE HOME CHF 510,000

The >>venture>> startup competition is holding its award ceremony tonight, and the grand prize winner will take home 150,000 Swiss francs. The founder of the annual contest, Thomas Knecht, shares his thoughts on what makes a successful entrepreneur and how to nurture venture capitalism in Switzerland.

BREMGARTER MAKES THE OCEANS SAFER

Swiss Ocean Tech has won second place in the leading Swiss startup competition >>venture>> in the Industrials & Engineering category. “This is incredibly motivating,” says founder Thomas Frizlen.

HIGHER EDUCATION: EVERYONE CAN BE AN ENTREPRENEUR

The Swiss Federal Institutes of Technology in Lausanne and Zurich are renowned breeding grounds for startups. But increasingly other universities in French-speaking Switzerland are also positioning themselves on the entrepreneurial front. [...] But not on equal terms “Polytechnics can develop their own technologies and bring them to market,” says Léa Firmin, CEO of the Venture Foundation. Fabian Greub from the Université de Neuchâtel stresses the question of means. “The Swiss Federal Institutes of Technology have a total budget of more than 3.5 billion Swiss francs!”

WOMEN STORM A MAN’S WORLD. THESE ARE THE INVENTORS OF THE YEAR.

Fajer Mushtaq recently won first prize in the >>venture>> awards, Switzerland’s largest startup competition, with her startup Oxyle. Carmen Escano (38) and Silvia Marquez (35) also want to contribute to managing a global environmental problem with their nascent company Nuniq, which is active in plastic waste reduction.
SUCCESS STORY

PLANTED

2019 — venture Audience Award
from left: Christoph Jenny, Pascal Bieri, Lukas Böni, Judith Wemmer, Eric Stirnemann
CHICKEN 2.4

Planted produces meat from plants.
After the success with artificial chicken, they are tinkering with other types of meat.

Lunchtime in the Kraftwerk Restaurant on the Sihl River in Zurich. Pre-pandemic. Two young women are sitting next to one another looking at the menu. “Planted chicken?” one of them asks. “No, not for me,” says the other. “I’m vegetarian.”

Pascal Bieri smiles as he monitors the conversation from the next table. “We still need to get the word out,” he says. Planted Chicken is the brainchild of four entrepreneurs from the ETH milieu. Their product: meat that doesn’t involve any animals being killed.

This scene at the restaurant played out in the fall of 2019. Not only were the pandemic and the lockdown a long way in the future but Planted was just beginning to have some success. At the time, the startup was producing some 300 kilograms of plant-based meat per day in an ETH lab. Most of the work was done manually by a small team.

Today Planted has around sixty-five employees in a number of different countries, and production now takes place on a massive scale: up to 8 tons per day. Planted has
evolved into a brand whose reputation extends far and wide. Its products can be found in the Swiss chains Coop and Migros and in Edeka and Spar in Germany and Austria.

The company headquarters has also grown: in summer 2020, Planted moved into spacious premises on the former Maggi site in Kemptthal. “A good deal has happened since we last met,” jokes Bieri on the phone. His team of entrepreneurs includes his cousin Lukas Böni and Eric Stirnemann, both of whom are food engineers at ETH, as well as Christoph Jenny. Bieri himself studied innovation management at the University of St. Gallen.

Judith Wemmer is a relatively new addition to the management team. Forbes recently selected her as one of the top “30 Under 30” in Switzerland, Germany, and Austria. The food scientist is head of product development at Planted. And there’s plenty happening there, with the company range constantly expanding. A few months back, they launched Planted Kebab: “The kebab that’s more fab.” Another new line is Planted Pulled, a pork substitute made of oat and sunflower proteins. To keep up with demand, automated production has been stepped up from the manual 2019 levels.

For all the changes, much has stayed the same: all Planted products are still chemical-free. The chicken, for example, still contains just four plant-based ingredients combined in a sophisticated manufacturing process: yellow split pea protein, pea fiber, sunflower oil, and water. The result is amazing. It looks and tastes just like real chicken, and it’s almost impossible to tell the two apart. It’s a similar story with the other products.
Planted is banking on a trend—meat consumption which doesn’t involve animal suffering—that has gained enormous traction in recent years. Investors have injected millions of dollars into startups like Mosa Meat and Beyond Meat. Planted’s founders also sensed the buzz. They launched their project in 2017 and formally incorporated their company in June 2019. A few months later, at the end of October, they successfully negotiated their first round of financing, promptly reeling in 7 million francs. The backers included familiar names like veggie king Rolf Hiltl, Philippe Gaydoul, who inherited the Denner supermarket group, and philanthropist Stephan Schmidheiny. The ETH Foundation also donated money from its spin-off fund. “A lot of people put their trust in us,” says Pascal Bieri. “We don’t want to disappoint.”

Then there are the prizes. In 2019, Planted won the >>venture>> Audience Award. On top of the 10,000-franc prize money, the competition brought prestige and a number of useful contacts. As Bieri recalls, the award was instrumental in giving the company greater visibility: “These kinds of prizes quickly turn you into a household name and increase your credibility.”

Given the Covid crisis, it’s also very important to have more stores selling the Planted line. Just as the company’s products were starting to feature on the menus of more and more eateries across Switzerland, “the restaurant closures carved off a significant chunk of turnover,” says Bieri. Luckily, they had a variety of distribution channels in place ahead of time.
In summer 2020, Planted moved into spacious premises on the former Maggi site in Kemptthal.
Planted carries out regular surveys on taste, texture, consistency, “bite,” and a range of other aspects.
There were other factors that made 2020 a challenging year. The task was to provide a sense of cohesion to a rapidly expanding team despite all the restrictions and having to work from home. This worked out well. “It’s a source of great pride,” says cofounder Lukas Böni. He’s also proud that the whole Planted team is always working to improve its products—and constantly asking questions of itself. “It’s all a work in progress,” says Böni. In this respect, the company functions like a tech startup. “We quantify everything and our discussions are based entirely on the data.” They carry out regular surveys on taste, texture, consistency, “bite,” and a range of other aspects. “This may sound a bit abstract, but it works well for us.”

The startup also has contact with conventional meat producers. “We test, cook, and keep developing,” says Bieri. Unlike in the regular meat industry, where a new spicy sausage is regarded as a major innovation, quite a bit of basic research is called for here. Planted’s products improve incrementally like computer programs—the versions even have numbers: the chicken is now on version 2.4, with Pulled Pork on 1.1.

When Bieri talks like this about the products, it can sound rather technocratic. The St. Gallen graduate doesn’t come across as some starry-eyed idealist—though he has all the arguments for plant-based meat substitutes up his sleeve. It’s obvious to him that ten billion people can’t continue to be fed the way they are today. “We need new, healthier options that are more efficient and more sustainable.”
But they’re not out to re-educate people. “That won’t work,” says Bieri, who founded the Lucerne branch of the Green Liberal Party some time ago with a group of colleagues. In his opinion, the meat-free alternative needs to be good enough and cheap enough to make consumers switch of their own accord. His team is not dogmatic either. It includes people with a broad spectrum of dietary preferences: from flexitarians to vegans.

For Böni, arguing about such categories is beside the point. Planted envisages a future in which customers have a free choice of animal and vegetable proteins at a protein counter. In this scenario, it may not even be about achieving a perfect meat imitation—but simply a matter of having “tasty, nutritious textured proteins” to eat.

Looking ahead, Planted has already set itself some fairly specific medium-term goals: having entered the German and Austrian markets, the company wants to expand into other European countries, like the UK and France.

In the meantime, the Planted team on the former Maggi site wants to keep refining its products—not behind the kind of thick walls you have in a slaughterhouse but as transparently as possible. “We have nothing to hide,” says Bieri. There are also plans for an on-site restaurant, where visitors will be able to taste the future of nutrition for themselves.

TEXT Daniel Fritzsche
Planted doesn’t re-educate consumers. They should switch to plant-based meat of their own accord.
Advisory Board 2020

Valentin Chapero
Francisco Fernandez
Pascal Kiener
Basil Heeb
Suzanne Thoma
Calvin Grieder
Hariolf Kottmann
Didier Denat
Dirk Lambrecht
Dieter Bambauer
Bruno Chiomento
Christian Buhl
Christoph Loos
Christian Keller
Alban Fischer
Julian Bertschinger
Christiane Leister
Frank Rehfeld
Thomas Kühne
Mauro Saladini
Frank Lehmann
Anja König
Severin Schwan
Felix Mayer
Jos Dijsselhof
Urs Baertschi
Marc Bürki
Axel Lehmann
Michael Müller
Zeno Staub
Matthias Reinhart
Juan Beer

Media partners

Pascal Crittin
Pietro Supino
Advisory Board 2021

Valentin Chapero
Philipp Rickenbacher
Pascal Kiener
Basil Heeb
Jürgen Eckhardt

Suzanne Thoma
Calvin Grieder
Francisco Fernandez
Conrad Keijzer
Dirk Lambrecht

Roberto Cirillo
Christian Buhl
Carlo Centonze
Christoph Loos
Alban Fischer

Julian Bertschinger
Christiane Leister
Frank Rehfeld
Thomas Kühne
Patrick Amstutz

Mauro Saladini
Frank Lehmann
Anja König
Severin Schwan
Walter Vogel

Felix Mayer
Jos Dijssehof
Arnd Kaldowski
Urs Baertschi
Marc Bürki

Sabine Keller-Busse
Michael Müller
Matthias Reinhart
Juan Beer

Media partners

Pascal Crittin
Pietro Supino
Young entrepreneurs are full of ideas and zest for action. But few could have formed thriving companies without the guidance of more than 200 mentors and jurors, who spent countless hours supporting >>venture>> participants—for free.

Godmothers and Godfathers of Success

A
Adamus, Nick
Allot, Pascal
Amraoui, Abdelaziz
Armalé, Ruth
Aschwanden, Manuel

B
Banz, Oliver
Bartos, Michal
Basic, Emrah
Baumann, Brigitte
Becker, René
Beranek, Zanon Nicole
Berger, Mark
Berini, Gian-Luigi
Binz, Kaspar
Bjonness, Soren
Blarer, Stefan
Blossfeld, Ivonne
Bocchetti, Salvatore
Boella, Marco
Boichat, Romain
Bolt, Urs
Bolte, Axel
Bong, Andreas
Brahme, Hanna
Brandenburger, Daniel
Braun, Aron
Brunner, Ronnie
Buck, Susanne
Budmiger, Pol
Buhler, Peter
Bührer, Adrian
Buller, Fabian

C
Caritey, Julien
Claesson, Ulf
Colombo, Mario

D
Dahinden, Daniel
Dantone, Matthias
Diemers, Daniel
Dieudonné-Vatran, Antoine
Diezi, Daniel
Döbelin, Lukas
Dübendorfer, Thomas
Duvanel, Thierry

E
Eisele, Thomas
Eleveld, Rolf
Enzler, Alex
Ernst, Bettina

F
Fabbroni, Marcello
Felber, Josef
Ferrari, Aldo
Florin, Claude
Foery, Thomas
Fülscher, Jan

G
Gall, Ralf
Gambardella, Antonio
Garcia, Pedraza Marcos
Geiger, Stefan
Gérardin, Luc
Golliard, Thierry
Gonzalez, Melanie
Grabulovski, Dragan
Grieder, Pascal
Grüning, Wolfram
Gygax, Ruedi

J
Jaccard, Michel
Jain, Nikhil
Janzi, Damian
John, Corinne

K
Kaiser, Verena
Kalt, Adrian
Kaltofen-Ehmann, Arnd
Kaufmann, Pascal
Keiser, Olivier
Kerscher, Thomas
Klocke, Björn
Knecht, Stephan
Kobel, Olivier
Koch, Hermann
Kraak, Marjan
Kramer, Axel
Kreyssel, Matthias
Kubli, Andreas
Kuhlen, Francis
Kuhn, Peter
Kunz, Jean-Philippe
Kyora, Stefan
Lanfear, Matt
Lang, Markus
Lattuada, Mauro
Lauchnauer, Frédéric
Lewis, Jim
Lohrer, Minja
Lonnen, Rana
Looser, Walter
Lucchina, Massimo
Lukas, Wilma
Lutz, Paulina

Mähr, Christian
Massignani, Marzia
Matthews, Donat
Maurice, Alexandre
Melo da Silva Ferreira, Rui Manuel
Meyer, Manuel
Millard, John
Moesching, Sylvain
Mohr, Vivian
Moser, Markus
Müller, Eduard
Mutz, Cédric

Nebel, Simon

Patrick, David
Petersen, Claudia
Petrichtche, Andrey
Piquet, Karim
Pitton Yves
Plötz A. Peter
Plüss, Andreas
Polydor, Sylvia
Prundaru, Ioana

Reinhardt, Lukas
Reitgassl, Frank
Rejman, Lucie
Roman, Johan
Roth, Balz
Roth, Simon
Rubner, Dennis
Ruchti, Christoph
Rüedi, Marco

Sailer, Damian
Sailer, Isabelle
Scheel, Hilmar
Scheller, Gerd
Scheuring, Luca
Schliess, Ralph
Schläpfer, Alexander
Schlenker, Andreas
Schneider, Martin
Schneider, Shila

Schön, Frank
Schubiger, Franz
Schwarzenbach, Andy
Seidel, Alex
Sidler, Michael
Siebenbürger Hacki, Katrin
Sierra, Raimundo
Spaeti, Philipp
Spycher, Bernard
Steiner, Ulrich
Stemmler, Franziska
Stender, Urs
Stephan, Véronique
Stöckl, Alex
Stucky, Michael
Stutz, Frido
Suter, Christian
Svoboda, Tomas

Tazi, Amine
Thar, Evelyn
Thévoz, Patrick
Thiel, Alexander
Tribalat, Fanny

Ullman, Fredrik

Van den Oever, Jeroen
van den Toorn, Willemien
van der Wolde, Aimée
Van Hautekerke, Charlotte
Vass, Francesco
Vilhena, Sabrina
Visarius, Heiko

Wacker, Michael
Wagner, Karen
Walcott, Arijana
Walser, Monika
Walther, Beat
Weder, Lukas
Weingarten, Kurt
Wibmer, Jeannette
Widmer, Simon
Williams, Virginia
Wolf, Matthias
Wolff de, Jean

Yu, David

Zimmermann, Claudia
Zimmermann, Krissy
The "venture" foundation 2020

Foundation Board
PREsIDENT
Thomas Knecht, Knecht Holding, Chairman
VICE PRESIDENT
André Hoffmann, Roche, Vice chairman
MEMBERS
André Kudelski, Innosuisse, President
Ulrich Jakob Looser, BLR & Partners, Partner
Joël Mesot, ETH Zurich, President
Martin Vetterli, EPFL, President
Marco Ziegler, McKinsey & Company, Senior partner

Steering Committee
Thomas Knecht, Knecht Holding, Chairman
Silvio Bonaccio, ETH Zurich, Head of ETH transfer
André Catana, EPFL, Head of Startup unit
Lea Firmin, "venture" foundation, CEO
Dominique Gruhl-Bègin, Innosuisse, Head of startups and next-generation innovators
Ulrich Jakob Looser, BLR & Partners, Partner
Marco Ziegler, McKinsey & Company, Senior partner

Office "venture"
Lea Firmin, "venture" foundation, CEO
Nathalie Geiger, "venture" foundation, Events & participant relations
Priscilla Sarnau, "venture" foundation, Marketing & communications
Maria Demontis, "venture" foundation, Marketing & events
Céline Korzepa, "venture" foundation, Events & participant relations
Martino Corti, EPFL, Marketing & communications
Galina Beliakova, EPFL, Events & participant relations
Lukas Steiner, McKinsey & Company, Jury & awards ceremony
Foundation Board

André Hoffmann
Roche

Marco Ziegler
McKinsey & Company

Thomas Knecht
Knecht Holding

Ulrich Jakob Looser
BLR & Partners

Joël Mesot
ETH Zurich

Martin Vetterli
EPFL

André Kudelski
Innosuisse